Biophysical screening for the discovery of small-molecule ligands.

Discovering small-molecule chemical probes of protein function has great potential to elucidate biological pathways and to provide early-stage proof-of-concept for target validation. Discovery of such probes therefore underpins many of the chemical biology and drug discovery efforts in both academia and the pharmaceutical industry. The process generally begins with screening small molecules to identify bona fide "hits" that bind non-covalently to a target protein. This chapter is concerned with the application of biophysical and structural techniques to small-molecule ligand screening, and with the validation of hits from both structural (binding mode) and energetic (binding affinity) stand-points. The methods discussed include differential scanning fluorimetry (thermal shift), fluorescence polarization (FP), surface plasmon resonance, ligand-observed NMR spectroscopy, isothermal titration calorimetry, and protein X-ray crystallography. The principles of these techniques and the fundamental nature of the observables used to detect macromolecule-ligand binding are briefly outlined. The practicalities, advantages, and disadvantages of each technique are described, particularly in the context of detecting weak affinities, as relevant to fragment screening. Fluorescence-based methods, which offer an attractive combination of high throughput and low cost are discussed in detail. It is argued that applying a combination of different methods provides the most robust and effective way to identify high-quality starting points for follow-up medicinal chemistry and to build structure-activity relationships that better inform effective development of high-quality, cell-active chemical probes by structure-based drug design.

[1]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[2]  Stephen W. Fesik,et al.  One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules , 1997 .

[3]  T. Willson,et al.  Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.

[4]  J F Brandts,et al.  Rapid measurement of binding constants and heats of binding using a new titration calorimeter. , 1989, Analytical biochemistry.

[5]  R. Spencer,et al.  High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.

[6]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[7]  T. Blundell,et al.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.

[8]  J. Broach,et al.  High-throughput screening for drug discovery. , 1996, Nature.

[9]  Maxwell D Cummings,et al.  Universal Screening Methods and Applications of ThermoFluor® , 2006, Journal of biomolecular screening.

[10]  C. Schalk-Hihi,et al.  Protein thermal shifts to identify low molecular weight fragments. , 2011, Methods in enzymology.

[11]  W Bruce Turnbull,et al.  On the value of c: can low affinity systems be studied by isothermal titration calorimetry? , 2003, Journal of the American Chemical Society.

[12]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[13]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[14]  Harald Schwalbe,et al.  Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.

[15]  Jean M. Severin,et al.  Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .

[16]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[17]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[18]  Stephen V Frye,et al.  The art of the chemical probe. , 2010, Nature chemical biology.

[19]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[20]  Julien Michel,et al.  Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.

[21]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[22]  G. Fogliatto,et al.  WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.

[23]  Maria Paola Costi,et al.  Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. , 2008, Journal of medicinal chemistry.

[24]  Tomas Lundqvist The devil is still in the details--driving early drug discovery forward with biophysical experimental methods. , 2005, Current opinion in drug discovery & development.

[25]  Chris Abell,et al.  Inhibition of Mycobacterium tuberculosis Pantothenate Synthetase by Analogues of the Reaction Intermediate , 2008, Chembiochem : a European journal of chemical biology.

[26]  Daniel A Erlanson,et al.  Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.

[27]  Craig M. Crews,et al.  Targeting the undruggable proteome: the small molecules of my dreams. , 2010, Chemistry & biology.

[28]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[29]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[30]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[31]  Stuart L Schreiber,et al.  Small molecules: the missing link in the central dogma , 2005, Nature chemical biology.

[32]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[33]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[34]  George T Detitta,et al.  Thermofluor-based high-throughput stability optimization of proteins for structural studies. , 2006, Analytical biochemistry.

[35]  K. Strebhardt,et al.  A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. , 2008, Analytical biochemistry.

[36]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[37]  P. Cole,et al.  Chemical probes for histone-modifying enzymes. , 2008, Nature chemical biology.

[38]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[39]  Chris Abell,et al.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.

[40]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[41]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[42]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[43]  Xinyi Huang,et al.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. , 2003, Journal of biomolecular screening.

[44]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[45]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[46]  S. Knapp,et al.  Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.

[47]  Chris Abell,et al.  Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.

[48]  Brian K Shoichet,et al.  Interpreting steep dose-response curves in early inhibitor discovery. , 2006, Journal of medicinal chemistry.